ALOX15B and PPARG |
arachidonate 15-lipoxygenase, type B |
peroxisome proliferator-activated receptor gamma |
- Arachidonic acid metabolism
- Metabolism of lipids and lipoproteins
- Synthesis of 15-eicosatetraenoic acid derivatives
|
- PPARA activates gene expression
- Fatty acid, triacylglycerol, and ketone body metabolism
- Metabolism of lipids and lipoproteins
- Generic Transcription Pathway
- Transcriptional regulation of white adipocyte differentiation
- Nuclear Receptor transcription pathway
- Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
|
|
- Icosapent
- Troglitazone
- Mesalazine
- Indomethacin
- Rosiglitazone
- Nateglinide
- Sulfasalazine
- Repaglinide
- Telmisartan
- Balsalazide
- Ibuprofen
- Glipizide
- Pioglitazone
- Mitiglinide
- Bezafibrate
- (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid
- 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID
- (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid
- 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid
- (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid
- (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid
- (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid
- (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid
- difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron
- (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID
- 3-(5-methoxy-1H-indol-3-yl)propanoic acid
- 3-{5-methoxy-1-[(4-methoxyphenyl)sulfonyl]-1H-indol-3-yl}propanoic acid
- (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid
- 2-chloro-5-nitro-N-phenylbenzamide
- (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid
- 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid
- 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID
- (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid
- 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE
- (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
- ALEGLITAZAR
|
|
|
ANK1 and ITPR3 |
ankyrin 1, erythrocytic |
inositol 1,4,5-trisphosphate receptor, type 3 |
- Interaction between L1 and Ankyrins
- CHL1 interactions
- Axon guidance
- Neurofascin interactions
- NrCAM interactions
- L1CAM interactions
|
- Signaling by the B Cell Receptor (BCR)
- Signaling by GPCR
- Glucagon-like Peptide-1 (GLP1) regulates insulin secretion
- Signaling by FGFR in disease
- Phospholipase C-mediated cascade
- Integration of energy metabolism
- Signaling by Wnt
- Signaling by EGFRvIII in Cancer
- PLCG1 events in ERBB2 signaling
- Effects of PIP2 hydrolysis
- Platelet calcium homeostasis
- DAP12 signaling
- Gastrin-CREB signalling pathway via PKC and MAPK
- Role of phospholipids in phagocytosis
- Fcgamma receptor (FCGR) dependent phagocytosis
- Signaling by PDGF
- DAP12 interactions
- Opioid Signalling
- EGFR interacts with phospholipase C-gamma
- Signaling by ERBB2
- G alpha (q) signalling events
- Signaling by EGFR
- GPCR downstream signaling
- Platelet homeostasis
- Signaling by VEGF
- Downstream signal transduction
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- Platelet activation, signaling and aggregation
- Adaptive Immune System
- G alpha (q) signalling events
- DAG and IP3 signaling
- VEGFA-VEGFR2 Pathway
- VEGFR2 mediated cell proliferation
- Downstream signaling of activated FGFR
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Innate Immune System
- Signalling by NGF
- PLC beta mediated events
- Regulation of insulin secretion
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- G-protein mediated events
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Signaling by FGFR
- beta-catenin independent WNT signaling
- Ca2+ pathway
- Elevation of cytosolic Ca2+ levels
- PLC-gamma1 signalling
- FCERI mediated Ca+2 mobilization
|
|
|
|
|
APP and CDKN2B |
amyloid beta (A4) precursor protein |
cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) |
- Signaling by GPCR
- Platelet degranulation
- Metabolic disorders of biological oxidation enzymes
- RIP-mediated NFkB activation via ZBP1
- Formyl peptide receptors bind formyl peptides and many other ligands
- Amyloids
- Toll Like Receptor TLR1:TLR2 Cascade
- Peptide ligand-binding receptors
- Toll Like Receptor 5 (TLR5) Cascade
- The NLRP3 inflammasome
- Gastrin-CREB signalling pathway via PKC and MAPK
- Response to elevated platelet cytosolic Ca2+
- MyD88 dependent cascade initiated on endosome
- Toll Like Receptor 9 (TLR9) Cascade
- G alpha (i) signalling events
- TRIF-mediated TLR3/TLR4 signaling
- Toll Like Receptor 2 (TLR2) Cascade
- G alpha (q) signalling events
- GPCR downstream signaling
- Toll Like Receptor 4 (TLR4) Cascade
- Toll Like Receptor 3 (TLR3) Cascade
- Platelet activation, signaling and aggregation
- TAK1 activates NFkB by phosphorylation and activation of IKKs complex
- Defective ACTH causes Obesity and Pro-opiomelanocortinin deficiency (POMCD)
- G alpha (q) signalling events
- Class A/1 (Rhodopsin-like receptors)
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- Toll Like Receptor TLR6:TLR2 Cascade
- DEx/H-box helicases activate type I IFN and inflammatory cytokines production
- Activated TLR4 signalling
- MyD88 cascade initiated on plasma membrane
- ZBP1(DAI) mediated induction of type I IFNs
- ECM proteoglycans
- MyD88:Mal cascade initiated on plasma membrane
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- Advanced glycosylation endproduct receptor signaling
- Innate Immune System
- Inflammasomes
- Cytosolic sensors of pathogen-associated DNA
- MyD88-independent cascade
- GPCR ligand binding
- Toll-Like Receptors Cascades
- RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
- Toll Like Receptor 10 (TLR10) Cascade
- Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
- TRAF6 mediated NF-kB activation
|
- Loss of Function of TGFBR2 in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- Cellular Senescence
- Oncogene Induced Senescence
- TGFBR1 LBD Mutants in Cancer
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
- Generic Transcription Pathway
- Mitotic G1-G1/S phases
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- G1 Phase
- Senescence-Associated Secretory Phenotype (SASP)
- TGFBR1 KD Mutants in Cancer
- Cell Cycle, Mitotic
- Loss of Function of TGFBR1 in Cancer
- Cyclin D associated events in G1
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- Oxidative Stress Induced Senescence
- SMAD4 MH2 Domain Mutants in Cancer
|
|
|
|
|
APP and INS |
amyloid beta (A4) precursor protein |
insulin |
- Signaling by GPCR
- Platelet degranulation
- Metabolic disorders of biological oxidation enzymes
- RIP-mediated NFkB activation via ZBP1
- Formyl peptide receptors bind formyl peptides and many other ligands
- Amyloids
- Toll Like Receptor TLR1:TLR2 Cascade
- Peptide ligand-binding receptors
- Toll Like Receptor 5 (TLR5) Cascade
- The NLRP3 inflammasome
- Gastrin-CREB signalling pathway via PKC and MAPK
- Response to elevated platelet cytosolic Ca2+
- MyD88 dependent cascade initiated on endosome
- Toll Like Receptor 9 (TLR9) Cascade
- G alpha (i) signalling events
- TRIF-mediated TLR3/TLR4 signaling
- Toll Like Receptor 2 (TLR2) Cascade
- G alpha (q) signalling events
- GPCR downstream signaling
- Toll Like Receptor 4 (TLR4) Cascade
- Toll Like Receptor 3 (TLR3) Cascade
- Platelet activation, signaling and aggregation
- TAK1 activates NFkB by phosphorylation and activation of IKKs complex
- Defective ACTH causes Obesity and Pro-opiomelanocortinin deficiency (POMCD)
- G alpha (q) signalling events
- Class A/1 (Rhodopsin-like receptors)
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- Toll Like Receptor TLR6:TLR2 Cascade
- DEx/H-box helicases activate type I IFN and inflammatory cytokines production
- Activated TLR4 signalling
- MyD88 cascade initiated on plasma membrane
- ZBP1(DAI) mediated induction of type I IFNs
- ECM proteoglycans
- MyD88:Mal cascade initiated on plasma membrane
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- Advanced glycosylation endproduct receptor signaling
- Innate Immune System
- Inflammasomes
- Cytosolic sensors of pathogen-associated DNA
- MyD88-independent cascade
- GPCR ligand binding
- Toll-Like Receptors Cascades
- RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
- Toll Like Receptor 10 (TLR10) Cascade
- Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
- TRAF6 mediated NF-kB activation
|
- Synthesis, secretion, and deacylation of Ghrelin
- Insulin receptor signalling cascade
- Integration of energy metabolism
- Regulation of insulin secretion
- IRS-related events
- SHC-related events
- Insulin receptor recycling
- Peptide hormone metabolism
- IRS activation
- Regulation of beta-cell development
- Signal attenuation
- Regulation of gene expression in beta cells
- Insulin processing
- SHC activation
- Signaling by Insulin receptor
|
|
|
|
|
APP and PPARG |
amyloid beta (A4) precursor protein |
peroxisome proliferator-activated receptor gamma |
- Signaling by GPCR
- Platelet degranulation
- Metabolic disorders of biological oxidation enzymes
- RIP-mediated NFkB activation via ZBP1
- Formyl peptide receptors bind formyl peptides and many other ligands
- Amyloids
- Toll Like Receptor TLR1:TLR2 Cascade
- Peptide ligand-binding receptors
- Toll Like Receptor 5 (TLR5) Cascade
- The NLRP3 inflammasome
- Gastrin-CREB signalling pathway via PKC and MAPK
- Response to elevated platelet cytosolic Ca2+
- MyD88 dependent cascade initiated on endosome
- Toll Like Receptor 9 (TLR9) Cascade
- G alpha (i) signalling events
- TRIF-mediated TLR3/TLR4 signaling
- Toll Like Receptor 2 (TLR2) Cascade
- G alpha (q) signalling events
- GPCR downstream signaling
- Toll Like Receptor 4 (TLR4) Cascade
- Toll Like Receptor 3 (TLR3) Cascade
- Platelet activation, signaling and aggregation
- TAK1 activates NFkB by phosphorylation and activation of IKKs complex
- Defective ACTH causes Obesity and Pro-opiomelanocortinin deficiency (POMCD)
- G alpha (q) signalling events
- Class A/1 (Rhodopsin-like receptors)
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- Toll Like Receptor TLR6:TLR2 Cascade
- DEx/H-box helicases activate type I IFN and inflammatory cytokines production
- Activated TLR4 signalling
- MyD88 cascade initiated on plasma membrane
- ZBP1(DAI) mediated induction of type I IFNs
- ECM proteoglycans
- MyD88:Mal cascade initiated on plasma membrane
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- Advanced glycosylation endproduct receptor signaling
- Innate Immune System
- Inflammasomes
- Cytosolic sensors of pathogen-associated DNA
- MyD88-independent cascade
- GPCR ligand binding
- Toll-Like Receptors Cascades
- RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
- Toll Like Receptor 10 (TLR10) Cascade
- Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
- TRAF6 mediated NF-kB activation
|
- PPARA activates gene expression
- Fatty acid, triacylglycerol, and ketone body metabolism
- Metabolism of lipids and lipoproteins
- Generic Transcription Pathway
- Transcriptional regulation of white adipocyte differentiation
- Nuclear Receptor transcription pathway
- Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
|
|
- Icosapent
- Troglitazone
- Mesalazine
- Indomethacin
- Rosiglitazone
- Nateglinide
- Sulfasalazine
- Repaglinide
- Telmisartan
- Balsalazide
- Ibuprofen
- Glipizide
- Pioglitazone
- Mitiglinide
- Bezafibrate
- (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid
- 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID
- (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid
- 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid
- (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid
- (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid
- (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid
- (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid
- difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron
- (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID
- 3-(5-methoxy-1H-indol-3-yl)propanoic acid
- 3-{5-methoxy-1-[(4-methoxyphenyl)sulfonyl]-1H-indol-3-yl}propanoic acid
- (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid
- 2-chloro-5-nitro-N-phenylbenzamide
- (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid
- 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid
- 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID
- (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid
- 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE
- (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
- ALEGLITAZAR
|
|
|
APP and IFIH1 |
amyloid beta (A4) precursor protein |
interferon induced with helicase C domain 1 |
- Signaling by GPCR
- Platelet degranulation
- Metabolic disorders of biological oxidation enzymes
- RIP-mediated NFkB activation via ZBP1
- Formyl peptide receptors bind formyl peptides and many other ligands
- Amyloids
- Toll Like Receptor TLR1:TLR2 Cascade
- Peptide ligand-binding receptors
- Toll Like Receptor 5 (TLR5) Cascade
- The NLRP3 inflammasome
- Gastrin-CREB signalling pathway via PKC and MAPK
- Response to elevated platelet cytosolic Ca2+
- MyD88 dependent cascade initiated on endosome
- Toll Like Receptor 9 (TLR9) Cascade
- G alpha (i) signalling events
- TRIF-mediated TLR3/TLR4 signaling
- Toll Like Receptor 2 (TLR2) Cascade
- G alpha (q) signalling events
- GPCR downstream signaling
- Toll Like Receptor 4 (TLR4) Cascade
- Toll Like Receptor 3 (TLR3) Cascade
- Platelet activation, signaling and aggregation
- TAK1 activates NFkB by phosphorylation and activation of IKKs complex
- Defective ACTH causes Obesity and Pro-opiomelanocortinin deficiency (POMCD)
- G alpha (q) signalling events
- Class A/1 (Rhodopsin-like receptors)
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- Toll Like Receptor TLR6:TLR2 Cascade
- DEx/H-box helicases activate type I IFN and inflammatory cytokines production
- Activated TLR4 signalling
- MyD88 cascade initiated on plasma membrane
- ZBP1(DAI) mediated induction of type I IFNs
- ECM proteoglycans
- MyD88:Mal cascade initiated on plasma membrane
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- Advanced glycosylation endproduct receptor signaling
- Innate Immune System
- Inflammasomes
- Cytosolic sensors of pathogen-associated DNA
- MyD88-independent cascade
- GPCR ligand binding
- Toll-Like Receptors Cascades
- RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
- Toll Like Receptor 10 (TLR10) Cascade
- Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
- TRAF6 mediated NF-kB activation
|
- TRAF3-dependent IRF activation pathway
- RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
- Negative regulators of RIG-I/MDA5 signaling
- TRAF6 mediated IRF7 activation
- TRAF6 mediated NF-kB activation
- NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10
- Innate Immune System
|
|
|
|
|
ATF1 and HNF1B |
activating transcription factor 1 |
HNF1 homeobox B |
- CREB phosphorylation
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- CREB phosphorylation
- Toll Like Receptor TLR6:TLR2 Cascade
- Activated TLR4 signalling
- Toll Like Receptor TLR1:TLR2 Cascade
- MyD88 cascade initiated on plasma membrane
- Toll Like Receptor 5 (TLR5) Cascade
- MyD88 dependent cascade initiated on endosome
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- MyD88:Mal cascade initiated on plasma membrane
- Toll Like Receptor 9 (TLR9) Cascade
- Innate Immune System
- Signalling by NGF
- TRIF-mediated TLR3/TLR4 signaling
- MAP kinase activation in TLR cascade
- NGF signalling via TRKA from the plasma membrane
- MyD88-independent cascade
- Toll Like Receptor 2 (TLR2) Cascade
- Toll-Like Receptors Cascades
- Toll Like Receptor 10 (TLR10) Cascade
- Toll Like Receptor 3 (TLR3) Cascade
- Toll Like Receptor 4 (TLR4) Cascade
- MAPK targets/ Nuclear events mediated by MAP kinases
- Nuclear Events (kinase and transcription factor activation)
|
- Regulation of beta-cell development
- Regulation of gene expression in early pancreatic precursor cells
- Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells
|
|
|
|
|
KIF1A and PPARG |
kinesin family member 1A |
peroxisome proliferator-activated receptor gamma |
|
- PPARA activates gene expression
- Fatty acid, triacylglycerol, and ketone body metabolism
- Metabolism of lipids and lipoproteins
- Generic Transcription Pathway
- Transcriptional regulation of white adipocyte differentiation
- Nuclear Receptor transcription pathway
- Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
|
|
- Icosapent
- Troglitazone
- Mesalazine
- Indomethacin
- Rosiglitazone
- Nateglinide
- Sulfasalazine
- Repaglinide
- Telmisartan
- Balsalazide
- Ibuprofen
- Glipizide
- Pioglitazone
- Mitiglinide
- Bezafibrate
- (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid
- 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID
- (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid
- 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid
- (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid
- (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid
- (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid
- (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid
- difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron
- (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID
- 3-(5-methoxy-1H-indol-3-yl)propanoic acid
- 3-{5-methoxy-1-[(4-methoxyphenyl)sulfonyl]-1H-indol-3-yl}propanoic acid
- (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid
- 2-chloro-5-nitro-N-phenylbenzamide
- (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid
- 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid
- 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID
- (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid
- 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE
- (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
- ALEGLITAZAR
|
|
|
AVP and AVPR2 |
arginine vasopressin |
arginine vasopressin receptor 2 |
- Defective ACTH causes Obesity and Pro-opiomelanocortinin deficiency (POMCD)
- G alpha (q) signalling events
- Signaling by GPCR
- Vasopressin-like receptors
- G alpha (s) signalling events
- Vasopressin regulates renal water homeostasis via Aquaporins
- Class A/1 (Rhodopsin-like receptors)
- Metabolic disorders of biological oxidation enzymes
- GPCR ligand binding
- Aquaporin-mediated transport
- SLC-mediated transmembrane transport
- Transport of organic anions
- G alpha (q) signalling events
- GPCR downstream signaling
- Peptide ligand-binding receptors
- Gastrin-CREB signalling pathway via PKC and MAPK
- Transport of vitamins, nucleosides, and related molecules
- BMAL1:CLOCK,NPAS2 activates circadian gene expression
|
- Defective ACTH causes Obesity and Pro-opiomelanocortinin deficiency (POMCD)
- Signaling by GPCR
- Vasopressin-like receptors
- G alpha (s) signalling events
- Vasopressin regulates renal water homeostasis via Aquaporins
- Class A/1 (Rhodopsin-like receptors)
- Metabolic disorders of biological oxidation enzymes
- Aquaporin-mediated transport
- GPCR ligand binding
- GPCR downstream signaling
- Peptide ligand-binding receptors
|
|
- Desmopressin
- Vasopressin
- Conivaptan
- Terlipressin
- Tolvaptan
|
|
|
AVPR2 and GRK5 |
arginine vasopressin receptor 2 |
G protein-coupled receptor kinase 5 |
- Defective ACTH causes Obesity and Pro-opiomelanocortinin deficiency (POMCD)
- Signaling by GPCR
- Vasopressin-like receptors
- G alpha (s) signalling events
- Vasopressin regulates renal water homeostasis via Aquaporins
- Class A/1 (Rhodopsin-like receptors)
- Metabolic disorders of biological oxidation enzymes
- Aquaporin-mediated transport
- GPCR ligand binding
- GPCR downstream signaling
- Peptide ligand-binding receptors
|
- G alpha (q) signalling events
- G alpha (q) signalling events
- Signaling by GPCR
- GPCR downstream signaling
- Gastrin-CREB signalling pathway via PKC and MAPK
|
- Desmopressin
- Vasopressin
- Conivaptan
- Terlipressin
- Tolvaptan
|
|
|
|
CCND1 and CDKN2A |
cyclin D1 |
cyclin-dependent kinase inhibitor 2A |
- Chromatin organization
- Signaling by NOTCH
- Ubiquitin-dependent degradation of Cyclin D
- G1 Phase
- S Phase
- Cell Cycle, Mitotic
- RMTs methylate histone arginines
- Ubiquitin-dependent degradation of Cyclin D1
- Cyclin D associated events in G1
- Chromatin modifying enzymes
- Pre-NOTCH Transcription and Translation
- Pre-NOTCH Expression and Processing
- Mitotic G1-G1/S phases
|
- Cyclin D associated events in G1
- Oxidative Stress Induced Senescence
- G1 Phase
- Cellular Senescence
- Senescence-Associated Secretory Phenotype (SASP)
- Oncogene Induced Senescence
- Mitotic G1-G1/S phases
- Cell Cycle, Mitotic
- Oxidative Stress Induced Senescence
- Cellular Senescence
- Oncogene Induced Senescence
|
|
|
|
|
BCL2L1 and CDKN2A |
BCL2-like 1 |
cyclin-dependent kinase inhibitor 2A |
- Inflammasomes
- The NLRP1 inflammasome
- Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
- Programmed Cell Death
- BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members
- Innate Immune System
- Intrinsic Pathway for Apoptosis
|
- Cyclin D associated events in G1
- Oxidative Stress Induced Senescence
- G1 Phase
- Cellular Senescence
- Senescence-Associated Secretory Phenotype (SASP)
- Oncogene Induced Senescence
- Mitotic G1-G1/S phases
- Cell Cycle, Mitotic
- Oxidative Stress Induced Senescence
- Cellular Senescence
- Oncogene Induced Senescence
|
|
|
|
|
BCR and HNF1A |
breakpoint cluster region |
HNF1 homeobox A |
- Rho GTPase cycle
- Signaling by FGFR in disease
- Signaling by Rho GTPases
- Signaling by FGFR1 mutants
- Signaling by FGFR mutants
- Signaling by FGFR1 fusion mutants
|
- Regulation of beta-cell development
- Regulation of gene expression in beta cells
|
|
|
|
|
BGLAP and CTSH |
bone gamma-carboxyglutamate (gla) protein |
cathepsin H |
|
- MHC class II antigen presentation
- Adaptive Immune System
|
- Menadione
- Phytonadione
- Gamma-Carboxy-Glutamic Acid
- Gallium nitrate
|
|
|
|
BTK and PRKCQ |
Bruton agammaglobulinemia tyrosine kinase |
protein kinase C, theta |
- Signaling by the B Cell Receptor (BCR)
- DAP12 interactions
- Toll Like Receptor TLR6:TLR2 Cascade
- Toll Like Receptor 2 (TLR2) Cascade
- Toll Like Receptor TLR1:TLR2 Cascade
- DAP12 signaling
- Activated TLR4 signalling
- Toll-Like Receptors Cascades
- Toll Like Receptor 4 (TLR4) Cascade
- Fc epsilon receptor (FCERI) signaling
- MyD88:Mal cascade initiated on plasma membrane
- FCERI mediated Ca+2 mobilization
- Fcgamma receptor (FCGR) dependent phagocytosis
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Regulation of actin dynamics for phagocytic cup formation
- Adaptive Immune System
- Innate Immune System
|
- G alpha (q) signalling events
- Signaling by GPCR
- Downstream TCR signaling
- Axon guidance
- Effects of PIP2 hydrolysis
- FCERI mediated NF-kB activation
- Inactivation, recovery and regulation of the phototransduction cascade
- Gastrin-CREB signalling pathway via PKC and MAPK
- The phototransduction cascade
- Programmed Cell Death
- G alpha (z) signalling events
- Netrin-1 signaling
- Innate Immune System
- Apoptotic cleavage of cellular proteins
- Apoptotic execution phase
- Diseases associated with visual transduction
- G alpha (q) signalling events
- GPCR downstream signaling
- TCR signaling
- Visual phototransduction
- Fc epsilon receptor (FCERI) signaling
- Platelet activation, signaling and aggregation
- Adaptive Immune System
|
- Inositol 1,3,4,5-Tetrakisphosphate
|
- Staurosporine
- Phosphonothreonine
- Phosphonoserine
|
|
|
CANX and MTNR1B |
calnexin |
melatonin receptor 1B |
- Diseases of glycosylation
- Defective ALG14 causes congenital myasthenic syndrome (ALG14-CMS)
- Defective MGAT2 causes MGAT2-CDG (CDG-2a)
- Defective ALG1 causes ALG1-CDG (CDG-1k)
- Antigen Presentation: Folding, assembly and peptide loading of class I MHC
- Virus Assembly and Release
- Defective MOGS causes MOGS-CDG (CDG-2b)
- Influenza Life Cycle
- Defective ALG9 causes ALG9-CDG (CDG-1l)
- Defective MAN1B1 causes MRT15
- MHC class II antigen presentation
- Class I MHC mediated antigen processing & presentation
- N-glycan trimming in the ER and Calnexin/Calreticulin cycle
- Assembly of Viral Components at the Budding Site
- Defective ALG11 causes ALG11-CDG (CDG-1p)
- Defective ALG2 causes ALG2-CDG (CDG-1i)
- Post-translational protein modification
- Defective ALG3 causes ALG3-CDG (CDG-1d)
- Defective DPAGT1 causes DPAGT1-CDG (CDG-1j) and CMSTA2
- Defective B4GALT1 causes B4GALT1-CDG (CDG-2d)
- Influenza Infection
- Defective RFT1 causes RFT1-CDG (CDG-1n)
- Defective ALG6 causes ALG6-CDG (CDG-1c)
- Asparagine N-linked glycosylation
- Defective ALG8 causes ALG8-CDG (CDG-1h)
- Defective MPDU1 causes MPDU1-CDG (CDG-1f)
- Defective ALG12 causes ALG12-CDG (CDG-1g)
- Diseases associated with N-glycosylation of proteins
- Adaptive Immune System
- Calnexin/calreticulin cycle
|
- Defective ACTH causes Obesity and Pro-opiomelanocortinin deficiency (POMCD)
- Signaling by GPCR
- GPCR downstream signaling
- Class A/1 (Rhodopsin-like receptors)
- G alpha (i) signalling events
- Metabolic disorders of biological oxidation enzymes
- GPCR ligand binding
|
- Antihemophilic Factor
- Tenecteplase
|
- Ramelteon
- Melatonin
- Agomelatine
|
|
|
CASP3 and PRKCQ |
caspase 3, apoptosis-related cysteine peptidase |
protein kinase C, theta |
- SMAC binds to IAPs
- SMAC-mediated dissociation of IAP:caspase complexes
- SMAC-mediated apoptotic response
- Cytochrome c-mediated apoptotic response
- Caspase-mediated cleavage of cytoskeletal proteins
- Degradation of the extracellular matrix
- Role of DCC in regulating apoptosis
- Activation of caspases through apoptosome-mediated cleavage
- Activation of DNA fragmentation factor
- Apoptotic factor-mediated response
- Programmed Cell Death
- Intrinsic Pathway for Apoptosis
- Signalling by NGF
- Apoptotic cleavage of cellular proteins
- Cell death signalling via NRAGE, NRIF and NADE
- Apoptotic execution phase
- p75 NTR receptor-mediated signalling
- Stimulation of the cell death response by PAK-2p34
- Apoptotic cleavage of cell adhesion proteins
- Signaling by Hippo
- Apoptosis induced DNA fragmentation
- Extrinsic Pathway
- NADE modulates death signalling
|
- G alpha (q) signalling events
- Signaling by GPCR
- Downstream TCR signaling
- Axon guidance
- Effects of PIP2 hydrolysis
- FCERI mediated NF-kB activation
- Inactivation, recovery and regulation of the phototransduction cascade
- Gastrin-CREB signalling pathway via PKC and MAPK
- The phototransduction cascade
- Programmed Cell Death
- G alpha (z) signalling events
- Netrin-1 signaling
- Innate Immune System
- Apoptotic cleavage of cellular proteins
- Apoptotic execution phase
- Diseases associated with visual transduction
- G alpha (q) signalling events
- GPCR downstream signaling
- TCR signaling
- Visual phototransduction
- Fc epsilon receptor (FCERI) signaling
- Platelet activation, signaling and aggregation
- Adaptive Immune System
|
- Minocycline
- 5-[4-(1-Carboxymethyl-2-Oxo-Propylcarbamoyl)-Benzylsulfamoyl]-2-Hydroxy-Benzoic Acid
- 2-HYDROXY-5-(2-MERCAPTO-ETHYLSULFAMOYL)-BENZOIC ACID
- methyl (3S)-3-[(tert-butoxycarbonyl)amino]-4-oxopentanoate
- 1-METHYL-5-(2-PHENOXYMETHYL-PYRROLIDINE-1-SULFONYL)-1H-INDOLE-2,3-DIONE
- [N-(3-DIBENZYLCARBAMOYL-OXIRANECARBONYL)-HYDRAZINO]-ACETIC ACID
- 4-[5-(2-CARBOXY-1-FORMYL-ETHYLCARBAMOYL)-PYRIDIN-3-YL]-BENZOIC ACID
- (1S)-2-oxo-1-phenyl-2-[(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-5-yl)amino]ethyl acetate
- (1S)-1-(3-chlorophenyl)-2-oxo-2-[(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-5-yl)amino]ethyl acetate
- N-[3-(2-fluoroethoxy)phenyl]-N\'-(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-6-yl)butanediamide
|
- Staurosporine
- Phosphonothreonine
- Phosphonoserine
|
|
|
CBL and PRKCQ |
Cbl proto-oncogene, E3 ubiquitin protein ligase |
protein kinase C, theta |
- Signaling by the B Cell Receptor (BCR)
- Loss of Function of TGFBR2 in Cancer
- Signaling by FGFR in disease
- SMAD2/3 MH2 Domain Mutants in Cancer
- Interleukin-6 signaling
- TGF-beta receptor signaling activates SMADs
- TGFBR1 LBD Mutants in Cancer
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- Regulation of KIT signaling
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- Regulation of signaling by CBL
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Negative regulation of FGFR signaling
- EGFR downregulation
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- Cytokine Signaling in Immune system
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- Spry regulation of FGF signaling
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Loss of Function of TGFBR1 in Cancer
- Signaling by FGFR
- Signaling by EGFR
- Signaling by Interleukins
- Signaling by TGF-beta Receptor Complex
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by EGFR in Cancer
- Constitutive Signaling by EGFRvIII
- Interleukin-3, 5 and GM-CSF signaling
- SMAD4 MH2 Domain Mutants in Cancer
- Adaptive Immune System
|
- G alpha (q) signalling events
- Signaling by GPCR
- Downstream TCR signaling
- Axon guidance
- Effects of PIP2 hydrolysis
- FCERI mediated NF-kB activation
- Inactivation, recovery and regulation of the phototransduction cascade
- Gastrin-CREB signalling pathway via PKC and MAPK
- The phototransduction cascade
- Programmed Cell Death
- G alpha (z) signalling events
- Netrin-1 signaling
- Innate Immune System
- Apoptotic cleavage of cellular proteins
- Apoptotic execution phase
- Diseases associated with visual transduction
- G alpha (q) signalling events
- GPCR downstream signaling
- TCR signaling
- Visual phototransduction
- Fc epsilon receptor (FCERI) signaling
- Platelet activation, signaling and aggregation
- Adaptive Immune System
|
|
- Staurosporine
- Phosphonothreonine
- Phosphonoserine
|
|
|
CBL and PTPN22 |
Cbl proto-oncogene, E3 ubiquitin protein ligase |
protein tyrosine phosphatase, non-receptor type 22 (lymphoid) |
- Signaling by the B Cell Receptor (BCR)
- Loss of Function of TGFBR2 in Cancer
- Signaling by FGFR in disease
- SMAD2/3 MH2 Domain Mutants in Cancer
- Interleukin-6 signaling
- TGF-beta receptor signaling activates SMADs
- TGFBR1 LBD Mutants in Cancer
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- Regulation of KIT signaling
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- Regulation of signaling by CBL
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Negative regulation of FGFR signaling
- EGFR downregulation
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- Cytokine Signaling in Immune system
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- Spry regulation of FGF signaling
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Loss of Function of TGFBR1 in Cancer
- Signaling by FGFR
- Signaling by EGFR
- Signaling by Interleukins
- Signaling by TGF-beta Receptor Complex
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by EGFR in Cancer
- Constitutive Signaling by EGFRvIII
- Interleukin-3, 5 and GM-CSF signaling
- SMAD4 MH2 Domain Mutants in Cancer
- Adaptive Immune System
|
|
|
|
|
|
SERPINH1 and PPARG |
serpin peptidase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1) |
peroxisome proliferator-activated receptor gamma |
- Collagen formation
- Collagen biosynthesis and modifying enzymes
|
- PPARA activates gene expression
- Fatty acid, triacylglycerol, and ketone body metabolism
- Metabolism of lipids and lipoproteins
- Generic Transcription Pathway
- Transcriptional regulation of white adipocyte differentiation
- Nuclear Receptor transcription pathway
- Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
|
|
- Icosapent
- Troglitazone
- Mesalazine
- Indomethacin
- Rosiglitazone
- Nateglinide
- Sulfasalazine
- Repaglinide
- Telmisartan
- Balsalazide
- Ibuprofen
- Glipizide
- Pioglitazone
- Mitiglinide
- Bezafibrate
- (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid
- 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID
- (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid
- 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid
- (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid
- (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid
- (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid
- (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid
- difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron
- (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID
- 3-(5-methoxy-1H-indol-3-yl)propanoic acid
- 3-{5-methoxy-1-[(4-methoxyphenyl)sulfonyl]-1H-indol-3-yl}propanoic acid
- (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid
- 2-chloro-5-nitro-N-phenylbenzamide
- (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid
- 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid
- 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID
- (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid
- 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE
- (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
- ALEGLITAZAR
|
|
|